Figure 14.

29 year old woman with metastatic thymic carcinoma treated with peptide receptor radiotherapy (PRRT) with ¹⁷⁷Lutetium. (A) Baseline contrast enhanced chest CT prior to PRRT treatment shows the primary prevascular mass (M), lung metastasis (straight arrow) and metastatic mediastinal lymphadenopathy (curved arrows). (B) Axial fused PET/CT scan at the same level as A, using a somatostatin analogue, Ga ⁶⁸-DOTATATE, reveals DOTATATE uptake in the primary mass (M), lung metastasis (straight arrow) and mediastinal lymphadenopathy. (C) Contrast enhanced chest CT, following two peptide receptor radiotherapy (PRRT) with ¹⁷⁷Lutetium sessions show an impressive partial response with a decrease in size of the primary mass (M) and of the lung metastasis (straight arrow), with resolution of the mediastinal lymphadenopathy. (D) Axial fused Ga ⁶⁸-DOTATATE PET/CT scan at the same level as C, shows a corresponding marked decrease in DOTATATE uptake consistent with an impressive metabolic partial response.